The cuproptosis-immunity intersection remains at an early stage; key mechanistic findings require independent validation before clinical translation and core controversies regarding the universality of cuproptosis immunogenicity, the immune activation window of copper ions, and the clinical utility of cuproptosis biomarkers are outlined.
Abstract
Cuproptosis is a copper-dependent form of regulated cell death driven by copper binding to lipoylated tricarboxylic acid (TCA) cycle proteins. This interaction triggers aberrant protein aggregation, Fe-S cluster protein degradation, and mitochondrial proteotoxic stress, and its unique metabolic dependency distinguishes cuproptosis from apoptosis and ferroptosis. This review examines the bidirectional regulation between cuproptosis and anti-tumor immunity. Cuproptosis can promote dendritic cell maturation and CD8+ T cell-mediated immunity through immunogenic cell death (ICD), damage-associated molecular pattern release, and cGAS-STING pathway activation. Activated CD8+ T cells may in turn enhance tumor cell cuproptosis sensitivity via IFN-γ-STAT1-IRF1-driven FDX1 upregulation, forming a positive feedback loop. Conversely, direct copper toxicity toward T cells and NK cells, spatial heterogeneity of intratumoral copper distribution, and potential immunosuppressive cytokine release may counterbalance these immunostimulatory effects. We outline core controversies regarding the universality of cuproptosis immunogenicity, the immune activation window of copper ions, and the clinical utility of cuproptosis biomarkers. Translational strategies including copper ionophore-immunotherapy combinations, copper-based nano-delivery systems, and copper metabolism-based patient stratification are discussed. The cuproptosis-immunity intersection remains at an early stage; key mechanistic findings require independent validation before clinical translation.
Cuproptosis is a form of programmed cell death reported in 2022, characterized by copper ions directly binding to mitochondrial lipoylated proteins, inducing aberrant protein aggregation and destabilizing iron-sulfur cluster proteins, ultimately leading to cell death. Distinct from apoptosis, ferroptosis, and other kno...
Peng-Peng Li, Yang-Yang Gao, Wei Liu· Frontiers in Cell and Develo...· 0 citations
This review summarizes current understanding of the molecular mechanisms governing cuproptosis and ferroptosis and identifies unresolved questions concerning pathway specificity, temporal regulation, biomarker validation, and the clinical safety of systemic or prolonged therapeutic modulation.
Yuan-Yuan Li, F. Tay· Signal Transduction and Targ...· 0 citations
Osteosarcoma is characterized by early metastatic potential, frequent postoperative recurrence, and resistance to conventional chemotherapy, and therapeutic progress remains limited. Osteosarcoma may have exploitable vulnerabilities due to metal homeostasis and redox control dysregulation. However, metal-associated cyt...
Xue-Hai Liu, Lin-Zhu Li, Yu-Fei Yang et al.· American Journal of Cancer R...· 0 citations
Recent data published in Cell demonstrate that a Cu 2+ -dependent form of regulated cell death (RCD) commonly known as cuproptosis is immunogenic, resulting in the emission of damage-associated molecular patterns (DAMPs) by malignant cells and the initiation of an adaptive anticancer immune response that not only ampli...
Lorenzo Galluzzi, O. Kepp, G. Kroemer· Signal Transduction and Targ...· 0 citations
Cuproptosis is a recently identified form of regulated cell death. It is primarily driven by abnormal mitochondrial copper accumulation. Ferredoxin 1-dependent copper reduction promotes the pathological aggregation of lipoylated proteins involved in the tricarboxylic acid cycle and the loss of iron-sulfur cluster prote...
Xin-Yi Zhang, Ru-Fan Xu, Hong-Rui Zhang et al.· Brain Research Bulletin· 0 citations
A therapeutic framework for overcoming immunotherapy resistance, which may potentially convert the metabolic vulnerabilities of cancer cells into immunological activating signals, hypothesized to drive durable anti-tumor immunity is proposed.
Mamdouh A. Ragab, Mahmoud A. Seliem· Medical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.